Term
| The biogenic amine hypothesis suggests decreased levels of: |
|
Definition
|
|
Term
| 9 sx of major depression: |
|
Definition
1. depressed mood, most of the day nearly every day
2. deminished interest in activities
3. significant weight loss
4. insomnia/hypersomnia
5. psychomotor agitation
6. fatigue
7. feelings of worthlessness or guilt
8. deminished ability to think/concentrate
9. recurrent thought of death suicide wo a plan |
|
|
Term
| criteria for dx of depression: |
|
Definition
| 5 or more the 9 sx present during a 2wk period and represent a change in fxn. at least one of the sx is depressed mood or loss of interest or plesure |
|
|
Term
| 3 tx phases for antidepressant therapy: |
|
Definition
1. acute phase:6-10wks goal=remission
2. continual phase:4-9moafter remission is achieved goal=elim residual sx
3. maintenance phase: 12-36mo after remission, goal=prevention |
|
|
Term
|
Definition
|
|
Term
|
Definition
| separate episode of depression >6mo apart |
|
|
Term
| indication for life-long maintenance therapy: |
|
Definition
1. <40yo w more than 2 episodes
2. any age with more than 3 prior episod |
|
|
Term
| risk of depression recurrence is directly related to: |
|
Definition
| the number of past episodes |
|
|
Term
| generalyy chosen as first line AD due to safety in overdose and improved tolerability: |
|
Definition
|
|
Term
| aminoketone demonstrate reuptake properties at both the NE & DA reuptake pumps: |
|
Definition
|
|
Term
| sedative properties at low doses but increased doses decrease sedation: |
|
Definition
|
|
Term
|
Definition
| inhibit MOA increasing NE, 5HT & DA |
|
|
Term
|
Definition
1. phenelzine
2. tranylcypromine |
|
|
Term
|
Definition
1. selegiline
2. rasagiline |
|
|
Term
|
Definition
1. cholinergic blockade
2. cardiac conduction delays
3. sexual dysfunction
4. abrupt withdrawal cause cholinergic rebound |
|
|
Term
| 4 meds that decrease plasma concentration of TCAs |
|
Definition
1. barbituates
2. carbemazepine
3. EtOH
4. PHY |
|
|
Term
|
Definition
1. venlafaxine/desvenlofaxine
2. duloxetine |
|
|
Term
| adverse effects of venlafaxine+desvenlafaxine |
|
Definition
1. nausea
2. sexual dysfunction
3. increase diastolic BP |
|
|
Term
| venlafaxine + desvenlafaxine MOA: |
|
Definition
| inhibits 5HT reuptake at low doses and NE reuptake at hgiher doses |
|
|
Term
|
Definition
| inhibits 5HT and NE reuptake at all doses |
|
|
Term
| duloxetine adverse effects: |
|
Definition
| nausea, dry mouth , constipation, insomnia, sweating |
|
|
Term
| changes in pharmacotherapy for pts w partial response: |
|
Definition
| change the dose, augment the AD, or add psychotherapy |
|
|
Term
| 3 ADs for the elderly in order of preference: |
|
Definition
1. SSRI
2. bupropion
3. venlafaxine |
|
|
Term
| only FDA approved med for depression in pts <18yo: |
|
Definition
|
|
Term
| 2 AD not FDA approved for <18 but remain viable options: |
|
Definition
|
|
Term
| teratogenic effects of SSRIs: |
|
Definition
|
|
Term
| most commonly used and best tolerated tx for depression in pregnancy: |
|
Definition
|
|
Term
|
Definition
| pts who do not achieve remission after 2 AD trials |
|
|
Term
| 3 pharmacologic approaches to tx resistant pts: |
|
Definition
1. stop current AD start trial w unrelated agent
2. augment current med (lithium)
3. initiate use of antipsychotic to augment AD response (not FDA apprvd) |
|
|
